Navigation Links
Vyta Corp Acquires 100% Ownership of BIOAGRA, LLC
Date:11/5/2008

DENVER, Nov. 5 /PRNewswire-FirstCall/ -- Vyta Corp (OTC Bulletin Board: VYTC) today announced that it has reached a favorable settlement in its foreclosure litigation against BIOAGRA, LLC. Pursuant to the terms of the amicable agreement, Vyta Corp now controls 100% ownership interest in BIOAGRA, LLC, and Paul H. Metzinger, President and CEO of Vyta Corp, becomes the sole Manager, and only executive officer of BIOAGRA, LLC. Terms of the agreement are included in a Form 8-K filed today with the Securities and Exchange Commission, and can be viewed on its website at (http://www.sec.gov).

BIOAGRA, LLC manufactures, markets and distributes AGRASTIM(R), a proprietary all-natural, biologically active yeast Beta-1,3/1,6-D-glucan feed supplement. AGRASTIM(R) has been listed by The Organic Materials Review Institute (OMRI) as approved for use in organic production.

About Vyta Corp

Vyta Corp, based in Denver, Colorado, is traded on the over-the-counter NASDAQ stock market (OTCBB: VYTC) as well as on the Frankfurt, Hamburg, XETRA and Munich Exchanges (OTC: VYTA).

In addition to its 100% ownership of BIOAGRA, LLC, Vyta Corp owns various patents and intellectual properties related to NCS(R) (NanoPierce Connection System) an advanced electronic connection system. For more information on Vyta Corp, please visit its website at http://www.vytacorp.com .

About BIOAGRA, LLC

BIOAGRA, LLC is based in Hinesville, Georgia, where it produces, markets and sells AGRASTIM(R), a purified, all natural, nontoxic yeast Beta 1,3/1,6-D glucan product with a high bioactivity function that improves the immune systems of animals and humans. AGRASTIM(R) is also used to replace growth promotion antibiotics that are currently used in the feed of the beef and dairy cattle, equine, swine, poultry and aquaculture industries.

This announcement contains forward-looking statements about Vyta Corp that may involve risks and uncertainties. Important factors relating to the Company's operations could cause results to differ materially from those in forward-looking statements and further detailed in filings with the Securities and Exchange Commission (SEC) available at the SEC website ( http://www.sec.gov ). All forward-looking statements are based on information available to Vyta Corp on the date hereof and Vyta Corp assumes no obligation to update such statements.

Contacts:

Vyta Corp

Paul H. Metzinger

President & Chief Executive Officer

370 17th St.

Suite 3640

Denver, CO 80202

303-592-1010

Fax: 303-592-1054

E-mail: paul@vytacorp.com


'/>"/>
SOURCE Vyta Corp
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech Acquires Pharmexas Diabody Technology
2. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
3. CPA Acquires Renowned German Patent Research Specialist, SVPG
4. Circassia Acquires North American and Japanese Rights to Dopexamine
5. Advanced Instruments Acquires D & F Control Systems Inc.
6. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
7. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
8. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
9. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
10. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
11. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... Scientists at the ... options being tried for mesothelioma may be hampering the research that could lead to ... Click here to read it now. , The team evaluated 98 ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® ... Farming in 2017 and Beyond. The paper outlines the key trends that are ... industry. , “We’ve witnessed a lot of highs and lows as the precision ...
Breaking Biology Technology:
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):